Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 63 recruiting now early-phase tilt #120 of 28,707 conditions

Breast Carcinoma: early-phase trial registry

63 of 107 indexed Breast Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #120 of 28,707 conditions by registered trial count.

107 US clinical trials · 63 currently recruiting · #120 of 28,707 conditions by registered trial count

Breast Carcinoma: 107 US clinical trials tracked, 63 recruiting.

Breast Carcinoma is the subject of 107 registered US clinical trials on ClinicalTrials.gov, 63 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 33 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 21 of these trials.

Enrollment posture brief

Registry condition breast-carcinoma

OPEN 63 | RECR 59% | LATE 5 | EARLY 33 | RANK #120 | SPON 21

Nearest open-share peer: Alcohol Use Disorder (59% recruiting · 185 trials)

Breast Carcinoma (this)59%Non-Hodgkin Lymphoma54.2%Cognitive Impairment43.4%Crohn's Disease34.9%Hepatitis C12%
Open-enrollment share among volume-matched conditions near Breast Carcinoma

Breast Carcinoma lists 63 open slots (59% of 107 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Breast Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Breast Carcinoma is recruiting above its size-band peers.

    63 of 107 indexed trials (58.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Breast Carcinoma research.

    Mayo Clinic accounts for 21 of 107 trials (19.6%). 30 distinct sponsors appear on at least one study for this condition label.

  3. Typical Breast Carcinoma enrolment sits around 126 participants.

    Median target enrolment is 126 among the 107 trials that report a genuine target (sentinel values excluded). 45 of those (42.1%) plan for fewer than 100 participants.

  4. Breast Carcinoma research is mostly interventional.

    77 interventional and 30 observational studies make up this index (72% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 115Phase 218Phase 35

Open and recent trials

107 total, page 2 of 3

RECRUITING 50 participants

Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women

Mayo Clinic

NCT05755269

RECRUITING NA 45 participants

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy

Mayo Clinic

NCT06055881

RECRUITING NA 40 participants

A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation

University of Washington

NCT06772181

RECRUITING Early Phase 1 40 participants

MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors

Mayo Clinic

NCT06274034

RECRUITING 30 participants

Surviving Daily Life

Thomas Jefferson University

NCT07054723

RECRUITING Phase 1 30 participants

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center

NCT07118176

RECRUITING 30 participants

A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer

Memorial Sloan Kettering Cancer Center

NCT06557148

RECRUITING Phase 2 27 participants

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Mayo Clinic

NCT07285044

RECRUITING NA 26 participants

Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer

City of Hope Medical Center

NCT04913064

RECRUITING Phase 1 24 participants

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

City of Hope Medical Center

NCT06130826

RECRUITING 20 participants

Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy

Mayo Clinic

NCT06953245

RECRUITING NA 20 participants

CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer

University of Michigan Rogel Cancer Center

NCT06915168

RECRUITING 12 participants

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

M.D. Anderson Cancer Center

NCT05406232

ACTIVE NOT RECRUITING Phase 2 6,452 participants

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

NCT02465060

ACTIVE NOT RECRUITING Phase 3 3,177 participants

Breast Cancer WEight Loss Study (BWEL Study)

Alliance for Clinical Trials in Oncology

NCT02750826

ACTIVE NOT RECRUITING NA 874 participants

Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer

Ohio State University Comprehensive Cancer Center

NCT05325151

ACTIVE NOT RECRUITING Phase 2 849 participants

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy

Immutep S.A.S.

NCT05747794

ACTIVE NOT RECRUITING NA 465 participants

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

City of Hope Medical Center

NCT04905082

ACTIVE NOT RECRUITING NA 337 participants

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members

M.D. Anderson Cancer Center

NCT02194387

ACTIVE NOT RECRUITING Phase 3 300 participants

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

Alliance for Clinical Trials in Oncology

NCT04711109

ACTIVE NOT RECRUITING NA 261 participants

Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study

Fred Hutchinson Cancer Center

NCT04081779

ACTIVE NOT RECRUITING Phase 3 216 participants

Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy

Alliance for Clinical Trials in Oncology

NCT04989504

ACTIVE NOT RECRUITING 140 participants

Long Term Followup of Patients Enrolled in MC1137, BEAUTY Study

Mayo Clinic

NCT05703399

ACTIVE NOT RECRUITING 140 participants

Evaluating Mechanical Properties of Post-Mastectomy Skin Flaps to Estimate Reconstruction Risks, the EMPOWER Study

M.D. Anderson Cancer Center

NCT06584396

ACTIVE NOT RECRUITING NA 134 participants

Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma

Washington University School of Medicine

NCT04849871

ACTIVE NOT RECRUITING Phase 1 134 participants

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Atavistik Bio

NCT07038369

ACTIVE NOT RECRUITING Phase 2 120 participants

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

University of California, Irvine

NCT02436993

ACTIVE NOT RECRUITING Phase 1 94 participants

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

NCT01366144

ACTIVE NOT RECRUITING NA 77 participants

Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma

Washington University School of Medicine

NCT03612648

ACTIVE NOT RECRUITING 59 participants

Contrast-Enhanced Mammography for the Evaluation of Mammographic Microcalcifications

M.D. Anderson Cancer Center

NCT05046301

ACTIVE NOT RECRUITING NA 50 participants

Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women

M.D. Anderson Cancer Center

NCT04267796

ACTIVE NOT RECRUITING Phase 2 42 participants

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

M.D. Anderson Cancer Center

NCT02876107

ACTIVE NOT RECRUITING Phase 2 36 participants

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

M.D. Anderson Cancer Center

NCT05226663

ACTIVE NOT RECRUITING NA 35 participants

Patient-Specific Decision Aid System for Shared Decision Making About Breast Reconstruction

M.D. Anderson Cancer Center

NCT05130580

ACTIVE NOT RECRUITING Phase 2 30 participants

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Providence Health & Services

NCT03650894

ACTIVE NOT RECRUITING NA 30 participants

An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction

M.D. Anderson Cancer Center

NCT03990610

ACTIVE NOT RECRUITING NA 30 participants

Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer

M.D. Anderson Cancer Center

NCT05132296

ACTIVE NOT RECRUITING Early Phase 1 29 participants

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Jonsson Comprehensive Cancer Center

NCT04147494

ACTIVE NOT RECRUITING Early Phase 1 27 participants

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

Julie L. Sutcliffe, Ph.D

NCT03164486

ACTIVE NOT RECRUITING Phase 1 27 participants

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

Washington University School of Medicine

NCT02204098

ACTIVE NOT RECRUITING Phase 2 8 participants

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Irada Ibrahim-zada

NCT05150652

COMPLETED 1,916 participants

Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Gynecologic Oncology Group

NCT01139957

COMPLETED Phase 3 1,363 participants

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

University of Rochester NCORP Research Base

NCT03367572

COMPLETED 324 participants

CARE: Cancer Risk Perception and Women of Color

Mayo Clinic

NCT06036875

COMPLETED Phase 1 230 participants

Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study

Mayo Clinic

NCT04456140

COMPLETED Phase 2 230 participants

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

NCT03180294

COMPLETED Phase 1 150 participants

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Xencor

NCT03517488

COMPLETED 85 participants

A Correlational Study: Breast Cancer-related Chest Wall Lymphedema, Quality of Life, and Shoulder Function

Mayo Clinic

NCT06285747

COMPLETED Early Phase 1 83 participants

MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer

Jonsson Comprehensive Cancer Center

NCT06090630

COMPLETED NA 66 participants

Fractional CO2 Laser Therapy for Survivors of Breast Malignancies

Ohio State University Comprehensive Cancer Center

NCT03307044

← Previous Page 2 of 3 Next →

Phase Distribution

PhaseTrial count
Phase 1 15
Phase 2 18
Phase 3 5

Named interventions

Most-linked intervention names on Breast Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
29 trials
Biospecimen Collection Procedure
19 trials
Survey Administration Other
12 trials
Non-Interventional Study Other
10 trials
Electronic Health Record Review Other
9 trials
Educational Intervention Other
9 trials
Laboratory Biomarker Analysis Other
8 trials
Interview Other
7 trials

US sites by state

Facility locations filed on Breast Carcinoma trials. A trial with sites in several states counts in each.

California 27 trials
Texas 22 trials
New York 15 trials
Florida 15 trials
Arizona 14 trials
Ohio 13 trials
Minnesota 13 trials
Michigan 9 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Breast Carcinoma page

107 registered trials, 63 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 63 Breast Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Mayo Clinic sponsors the most Breast Carcinoma trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Carcinoma condition card totals 107 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.